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Background: Sialic acid-binding Ig-like lectin-7 (Siglec-7) expression is strongly reduced on natural killer (NK) cells from
HIV-1 infected viremic patients. To investigate the mechanism(s) underlying this phenomenon, we hypothesized that
Siglec-7 could contribute to the infection of CD4pos target cells following its interaction with HIV-1 envelope (Env)
glycoprotein 120 (gp120).
Results: The ability of Siglec-7 to bind gp120 Env in a sialic acid-dependent manner facilitates the infection of both T
cells and monocyte-derived macrophages (MDMs). Indeed, pre-incubation of HIV-1 with soluble Siglec-7 (sSiglec-7)
increases the infection rate of CD4pos T cells, which do not constitutively express Siglec-7. Conversely, selective blockade
of Siglec-7 markedly reduces the degree of HIV-1 infection in Siglec-7pos MDMs. Finally, the sSiglec-7 amount is
increased in the serum of AIDS patients with high levels of HIV-1 viremia and inversely correlates with CD4pos
T cell counts.
Conclusions: Our results show that Siglec-7 binds HIV-1 and contributes to enhance the susceptibility to infection of
CD4pos T cells and MDMs. This phenomenon plays a role in HIV-1 pathogenesis and in disease progression, as
suggested by the inverse correlation between high serum level of sSiglec-7 and the low CD4pos T cell count observed
in AIDS patients in the presence of chronic viral replication.
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The human immunodeficiency virus type 1 (HIV-1) en-
velope (Env) glycoprotein 120 (gp120) is extensively
covered by carbohydrates that play an active role in the
viral life cycle. Indeed, besides forming a protecting
shield from antibody (Ab) recognition, this coat of N-
linked glycans affects the folding of viral glycoproteins
and virus infectivity [1-4]. gp120 N-linked glycans in-
clude 11 high-mannose or hybrid-type glycans and 13
complex-type glycans (containing terminal sialic acids)
that are highly conserved in different isolates and clades
[3,5]. Sialic acids are a family of sugars with a 9-carbon* Correspondence: domenico.mavilio@humanitas.it
3Unit of Clinical and Experimental Immunology, Humanitas Clinical and
Research Center, Rozzano, Milan, Italy
9Department of Medical Biotechnologies and Translational Medicine,
University of Milan, Milan, Italy
Full list of author information is available at the end of the article
© 2013 Varchetta et al.; licensee BioMed Cent
Commons Attribution License (http://creativec
reproduction in any medium, provided the orbackbone present at the ends of glycan chains in all cell
types [6,7]. They are recognized by many sugar-binding
proteins, including sialic acid-binding lectins (Siglecs), a
family of 16 I-type lectins showing a specific affinity for
different sialic acids. In particular, Siglec-7 preferentially
binds α(2,8)-linked disialic acid and α(2,6)-linked sialic
acid [8]. Siglec-7 is constitutively expressed on human
natural killer (NK) cells, monocytes and a small subset of
CD8pos T cells [9-13]. In regard to interactions with patho-
gens, Siglec-7 has been shown to bind Campylobacter
jejuni and Pseudomonas aeruginosa expressing or display-
ing sialic acids on their surface, respectively [14-16].
Many human lectin-type receptors including galectins
[17,18], defensins [19-21] and others [22-27] have been
shown to bind HIV-1 Env by recognizing glycans expressed
on gp120. However, these molecules may affect HIV-1 in-
fection in an opposite way as some, such as mannose-ral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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infection, while others, such as galectin-1, DC-SIGN [24],
mannose receptor [25], syndecan-3 [26] and DCIR [27], in-
crease the susceptibility to HIV-1 infection.
Recently, it has been shown that different Siglecs, such
as Siglec-1 and Siglec-7, recognize HIV-1 and enhance in-
fection of monocytes [28], macrophages [29] and dendritic
cells (DCs) [30]. Indeed, sialic acids present on Env gp120
can be recognized by Siglecs either expressed on these im-
mune cells or released in soluble forms, thus facilitating
viral entry into target cells. Although Siglec-7 has been
shown of being able to bind Env gp120 from different
HIV-1 strains with lower affinity if compared to Siglec-1
[29], very little is know about the role of Siglec-7 in partici-
pating to the HIV-1 infections of CD4pos target cells. We
have previously shown that the expression of Siglec-7 is
significantly reduced on the surface of NK cell from HIV-1
infected viremic patients and that the successful suppres-
sion of viral replication by antiretroviral therapy (ART)
restores Siglec-7 expression on these cells [31].
The present study demonstrates that, following its bind-
ing with HIV-1 Env gp120, Siglec-7 contributes to viral
entry and infection of both CD4pos T cells and monocyte-
derived macrophages (MDMs). Indeed, our results dem-
onstrate that the treatment with soluble Siglec-7-Fc fusion
protein increases the susceptibility to HIV-1 infection in
Siglec-7neg/CD4pos T cells, while blockade of Siglec-7 with
a specific Ab reduces the degree of infection in Siglec-7pos
MDMs. Finally, the study shows that in the sera of viremic
AIDS patients there are increased serum levels of soluble
Siglec-7 (sSiglec-7) that inversely correlates with CD4pos T
cell counts, thus suggesting a direct role of this glycan-
binding protein in the modulation of HIV-1 infection and
disease progression.
Results
Soluble Siglec-7 binds HIV-1 envelope gp120 recombinant
protein from different HIV-1 strains
On the basis of our previous report [31] showing a signifi-
cant reduction in Siglec-7 expression on NK cells from
HIV-1 viremic patients, we proceeded to confirm whether
Siglec-7 could directly interact with HIV-1 Env gp120 [29].
To this end, recombinant gp120 from HIV-1 IIIB virus
(produced in mammalian CHO cells) was conjugated to
carboxyl microparticles. We then evaluated the ability of
this complex to bind Siglec-7-Fc protein by flow cytometry.
As internal negative control, we used NKp44 Fc chimera.
We observed that the only Siglec-7 chimera, and not the
NKp44 one, has the ability to bind gp120 (Figures 1A-B
and 2A). The pre-incubation of Siglec-7 Fc fusion protein
with a pool of 2 different anti-Siglec-7 monoclonal Abs
(mAbs) (QA79 and Z176 clones) resulted in an inhibition
of the binding (Figure 1C, left panel), thus demonstrating
the specificity of the Siglec-7-HIV-1 interaction. Moreover,this binding appeared to be sialic acid-dependent, since
pre-treatment of gp120 with neuraminidase (NA) strongly
inhibits the interaction between Siglec-7 and the HIV-1 en-
velope protein (Figure 1C, right panel).
The ability of Siglec-7 to directly bind HIV-1 was then
assessed by using both R5 (BaL, SG) and X4 tropic (IIIB)
isolates in a virion-binding assay. Goat anti-human Fc mag-
netic beads coated with Siglec-7-Fc or NKp44-Fc proteins
were incubated with the HIV-1 infectious viral stocks, and
the binding was evaluated by measuring the amount of cap-
tured p24 HIV-1 antigen by ELISA. In line with the experi-
ments shown in the panels A-B-C of Figure 1, we found
detectable amounts of p24 only in the presence of Siglec-7-
Fc fusion protein coated beads and not after incubation
with beads coated with NKp44-Fc chimera, regardless of
the HIV-1 strains used. The binding of R5 or X4 HIV-1 iso-
lates to beads coated with the anti-gp120 mAb 2G12 was
used as positive internal control (Figure 2B).
Siglec-7 fusion protein enhances HIV-1 infection of CD4pos
T cells
Since we observed that Siglec-7 is able to bind gp120,
we sought to determine if this interaction could contribute
to HIV-1 infection at the cellular level. We first choose as
target PM1, a CD4pos T cell line known to be susceptible
to infection by different HIV-1 isolates, including primary
CCR5- and CXCR4-tropic tropic strains [32,33]. We incu-
bated for 1 hour the R5 (BaL) and X4 (IIIB) HIV-1 viral
stocks with Siglec-7- or NKp44- Fc chimeras and subse-
quently we infected PM1 cells. The degree of infection
was evaluated after 3 days of culture. PM1 cells infected
with either IIIB or BaL strains pre-incubated with Siglec-7
chimera showed a significant increase in HIV-RNA copies
compared to their counterparts infected with untreated
viral isolates (Figure 3A-B). No effects were observed
when PM1 cells were infected with HIV-1 strains pre-
incubated with NKp44 Fc fusion protein, thus confirming
again the specificity of Siglec-7 in enhancing the suscepti-
bility to HIV-1 infection.
We then investigated whether the Siglec-7 chimera was
able to amplify the HIV-1 productive infection also in pri-
mary CD4pos T cells, the main target of HIV infection
[34,35]. To this end, we followed the same protocol used
for PM1 cells. Again, our results showed a statistically sig-
nificant increase of HIV-1 viral load in CD4pos T cells in-
fected with HIV-1 IIIB pre-incubated with Siglec-7-Fc
chimera compared to their counterpart infected with un-
treated HIV-1 strains, while pre-incubation of viral isolates
with NKp44 fusion protein did not enhance the degree of
infection of CD4pos T cells (Figure 3C). Although, we
observed a higher HIV-1 viral load also in CD4pos T cells
infected with HIV-1 BaL pre-incubated with Siglec-7-Fc
chimera, this increase did not reach a statistical signifi-
cance (Figure 3D).
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Figure 1 Siglec-7 binds recombinant env gp120. A, Dot plot flow cytometry graphs showing representative examples of negative and
positive controls for the binding experiments reported in the 1B and 1C panels. The negative control graph (left) illustrates the absence of
interactions between env gp120 from HIV-1 IIIB strain covalently conjugated to carboxyl microparticles and phycoerythrin (PE)-labeled goat anti-human
(GAH). The positive control shows the binding of env gp120 from HIV-1 IIIB strain covalently conjugated to carboxyl microparticles to PE-labeled
anti-env gp120 mAb (clone 2G12). B, Dot plot flow cytometry graphs showing a representative example of the binding of NKp44 (left) or Siglec-7
(right) Fc fusion proteins to env gp120 from HIV-1 IIIB strain covalently conjugated to carboxyl microparticles. The binding was detected trough a
PE-labeled GAH Fc Ab conjugated to the fusion proteins. C, Dot plot flow cytometry graphs showing a representative example of the binding of
Siglec-7 Fc fusion protein to env gp120 from HIV-1 IIIB strain covalently conjugated to carboxyl microparticles in the presence of a pool of anti
Siglec-7-specifc antibodies (left) and of gp120 neuraminidase treatment (right).
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primary CD4pos T cells
To understand if the binding of Siglec-7 with HIV-1 gp120
protein effectively contributes to viral entry process into
target cells, we performed a 4-hour entry assay in CD4pos
T cells infected with either BaL or IIIB viral strains pre-
incubated with Siglec-7-Fc or NKp44-Fc fusion proteins.
The number of HIV-RNA copies detected in cell lysates
was significantly increased in CD4pos T cells infected with
IIIB and BaL strains pre-incubated with Siglec-7-Fc protein
but not in cells pre-treated with NKp44-Fc chimera com-
pared with control infections (Figure 4A-B).
T cells are generally considered not to express substantial
amounts of Fcγ receptors (FcγRs) although there are a few
reports showing a positive expression of CD64 (FcγRI),
CD32 (FcγRII) and CD16 (FcγRIII) on some CD4pos cell
line or unique primary T cell subsets [36,37]. Since our ex-
perimental approach relies on recombinant Siglec-7-Fc fu-
sion protein as a surrogate of sSiglec-7, we proceeded todemonstrate that the enhanced HIV entry/infection in
CD4pos T cell targets by Siglec-7-Fc is not associated with
the expression of FcγRs. To this end, we measured the sur-
face levels of CD64, CD32 and CD16 on PM1 cell lines and
primary CD4pos T cells by flow cytometry and we did not
detect any significant or bimodal expression of FcγRs on
the aforementioned populations compared to positive con-
trols (Additional files 1, 2 and 3).
Anti-Siglec-7 blocking Ab inhibits HIV-1 viral entry
in MDMs
MDMs are susceptible to HIV-1 infection as they express
both CD4 and the co-receptors CCR5 and CXCR4 [38,39].
However, unlike primary CD4pos T cells and similar to cir-
culating monocytes [13], MDMs constitutively express
high levels of Siglec-7 (Figure 4C), thus representing a use-
ful cellular model to study the Siglec-7/HIV-1 interaction.
Since we found that sSiglec-7 promotes HIV-1 entry into
CD4pos T cells, we asked whether blockade of this lectin-
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Figure 2 Siglec-7 interacts with recombinant env gp120 from different HIV-1 strains. A, Histogram bar graph showing cumulative results
representative of 7 different experiments (mean ± SD), whose representative example is showed in Figure 1B. B, Histogram bar graph showing
the amount of p24 core antigen detected by ELISA as indicative of the bindings of NKp44 and Siglec-7 Fc fusion proteins to different HIV-1 viral
strains. Data are representative of 2 independent experiments (mean ± SD). The binding of R5 or X4 HIV-1 isolates to beads coated with the
anti-gp120 mAb (clone 2G12) was used as positive internal control.
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degree of HIV-1 infection. To validate this hypothesis,
MDMs were cultured with HIV-1 BaL either with or with-
out a previous incubation with anti-Siglec-7 blocking Ab.
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Figure 3 Pre-incubation of soluble Siglec-7 protein with HIV-1 virus in
the copies/ml of HIV-RNA transcripts in the cell supernatant of PM1 cell line (A-B
strains pre-incubated or not with either NKp44 or Siglec-7 fusion proteins. DataMDM lysates 4 hours after infection to assess viral intern-
alization. The results showed that the masking of Siglec-7
induced a statistically significant decrease of HIV-RNA
copies compared to the infection performed in the ab-
sence of anti-Siglec-7 blocking Ab (Figure 4D).BAL sNKp44 sSiglec-7
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Figure 4 Soluble Siglec-7 facilitates HIV-1 entry in CD4pos T cells and MDMs. A-B, Histogram bar graph showing the copies/ml of HIV-RNA
transcripts in the CD4pos primary T cell lysates infected with IIIB (A) or BaL (B) viral strains either pre-incubated or not with either NKp44 or
Siglec-7 fusion proteins. C, Histogram flow cytometric graph from a representative example showing the surface expression of Siglec-7 on
monocytes (black line) and on MDMs (grey line) compared to isotype control (light gray line). D, Histogram bar graph showing the copies/ml of
HIV-RNA transcripts in the MDM cell lysates infected with BaL viral strain either in the absence or in the presence of a blocking polyclonal antibody
anti-Siglec-7. The related isotype control is included in the graph. Data are representative of 4 independent experiments (mean ± SD).
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infected patients naïve for antiretroviral therapy (ART)
Given the ability of the soluble form of this lectin-type re-
ceptor in enhancing the susceptibility to HIV-1 infection in
target cells, we then investigated whether or not sSiglec-7
plays a role in the natural course of HIV-1 infection by
quantifying its levels in the serum of 42 HIV seropositive
naïve patients, 13 AIDS patients, 54 aviremic patients
treated with antiretroviral therapy (ART) compared to 52
healthy donors (Table 1). We did not detect any significant
difference in serum levels of sSiglec-7 between healthy do-
nors and the different cohorts of HIV-1 infected patients.
However, AIDS patients displayed a trend toward increase
of serum Siglec-7 compared to healthy donors (Figure 5A).
Moreover, a significant increase of sSiglec-7 was ob-
served in the sera of naïve patients with viral load above
10,000 copies/ml compared with naïve patients withviral load below this level (Figure 5B). Although not sta-
tistically significant, a similar trend toward increase of
serum levels of sSiglec-7 was observed in naïve patients
with a CD4pos T cell count lower than 200/mm3 com-
pared with those with CD4pos T cell counts higher than
200/mm3 (Figure 5C).
Interestingly, the levels of sSiglec-7 directly correlated
with the HIV-1 viral load but not with the CD4pos T cell
count in untreated patients, while AIDS patients showed an
inverse correlation between the amount of sSiglec-7 and
the CD4pos T cell count. No correlation was found between
sSiglec-7 and HIV-RNA in AIDS patients (Figure 6).
Discussion
In this study, we show that the direct interaction between
Siglec-7 and HIV-1 Env gp120 contributes to HIV-1 entry
and infection of CD4pos cell targets, including T cells and
Table 1 Demographic and clinical features of HIV-1 infected patients
NAIVE¶ ART* AIDS# TOTAL
(n = 42) (n = 54) (n = 13) (n = 109)
Gender
Female 8 14 3 25
Male 34 40 10 84
Age (years)
Median 46 52 51 50
Range 22-53 38-66 47-75 22-75
Plasma HIV-1 RNA (copies/ml)
Median 16816 <50 46630 1620
Range 74-309691 0-412137 22025-402137 0-402137
CD4pos T cell count (cells/mm3)
Median 380 491 111.5 386.5
Range 99-1042 98-1328 3-197 3-1328
¶Naïve patients for antiretroviral therapy (ART) without a clinical history of opportunistic infections or malignancies associated to HIV-1 infection.
*ART included at least one protease inhibitor, one non-nucleoside reverse-transcriptase inhibitor and /or two nucleoside reverse-transcriptase inhibitors.
#Chronically HIV-1 infected patients either naïve for ART or therapeutic regimen had been discontinued at least 24 months earlier. Clinical history included
opportunistic infections or malignancies associated to HIV-1 infection.
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Figure 5 Serum level of soluble Siglec-7 is associated to viral load and CD4pos T cell counts. A, Dot plot graph showing the level of serum
Siglec-7 levels in healthy donors (HD), naïve, ART treated and AIDS patients (mean). B, A significant increase in serum Siglec-7 levels was observed
in naïve patients with viral load >10,000 copies/ml. C, sSiglec-7 was decreased in patients with CD4pos T cell cell count lower than 200/mm3.
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Figure 6 Correlations between sSiglec-7, CD4 cell counts and HIV-1 viral loads. A, Statistical analyses showing the correlation between the
levels of sSiglec-7 in the serum of naïve patients and HIV-1viremia. B, Statistical analyses showing the correlation between the levels of sSiglec-7
in the serum of AIDS patients and CD4pos T cell count. C, Statistical analyses showing the correlation between the levels of sSiglec-7 in the serum
of naïve patients and the CD4+ T cell count. D, Statistical analyses showing the correlation between the levels of sSiglec-7 in the serum of AIDS
patients and HIV-1 viremia.
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studies reporting that the interactions between sialic acids
present on the viral envelope and Siglec receptors facilitate
HIV-1 infection in several cellular targets [28-30].
Siglec molecules have been recognized as ligands of dif-
ferent sialic-acid bearing pathogens [13-15,40-44], al-
though it is still debated whether resting leukocytes with
masked Siglecs are able to directly engage sialic acids on
pathogens or if cell activation is required for unmasking
these lectin-type receptors. Originally, the interactions be-
tween Siglec receptors and pathogens were reported to
dampen host immune responses and to set appropriate ac-
tivation thresholds for regulating cell proliferation and
secretion of inflammatory mediators. Subsequently, it be-
came evident that this biological phenomenon represents
an advantage for pathogens that evolved to express sialic
acids on their surface to evade host innate immune re-
sponses [45,46]. However, recent evidence showed that si-
alic acid-expressing pathogens could also promote infectionand mediate immune responses following their binding to
Siglecs [13,47,48].
In line with a previous report [29], we demonstrate that
Siglec-7 is able to directly interact with HIV-1 Env gp120
although we found a certain degree of variability among
different HIV-1 strains. This phenomenon may have sev-
eral explanations, including deletions or mutations of crit-
ical residues involved in Siglec-7 binding or, most likely,
heterogeneity in HIV-1 glycosylation patterns [1-4,13].
Evidence in favor of the latter hypothesis comes from our
results showing that Siglec-7 interaction with HIV-1 is in-
deed sialic acid-dependent. In this regard, it has also been
reported that sialic acid depletion from human CD4pos tar-
get cells enhances HIV-1 infection [49]. This suggest that
removing cis-interactions between sialic acids and Siglecs
on the same cell leads to exposure of Siglecs that, in turn,
become accessible to sialic acids exposed on gp120. More-
over, oligomeric modeling of the gp120 trimer shows that
complex glycans are exposed on the outer rim, potentially
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recently been shown that different Siglecs, and Siglec-1 in
particular, are able to recognize both R5 and X4 HIV-1
gp120 through interaction with sialic acids, thus contribut-
ing to HIV-1 infection of monocytes, macrophages and
DCs [28-30].
The present study also provides evidence that Siglec-7
binds HIV-1 and enhances viral entry into CD4pos T cells
when the soluble form of this lectin-type molecule is added
to the culture. Indeed, our data clearly showed that Siglec-
7-Fc fusion protein is able to enhance IIIB and BaL infec-
tions both in a CD4pos T cell line (PM1) and in primary
CD4pos T cells, even though the levels of HIV-RNA were
higher for IIIB compared to BaL. This latter phenomenon
is likely due to the well-known preferential tropism of the
IIIB HIV-1 strain for T cells [51]. Further investigations fo-
cusing on the structures, biochemical properties and affin-
ity of these interactions are needed to confirm this working
hypothesis. Moreover, we also demonstrate that constitu-
tive expression of Siglec-7 on MDMs markedly contributes
to their HIV-1 infection, since specific Siglec-7 blockade in-
duced a reduction of HIV-RNA in MDMs in a 4-hour entry
assay. The degree of surface levels of Siglec-7 on monocytes
and macrophages is still being debated, as there is one
study showing that expression of this molecule on mono-
cytes and MDMs is very low [29], while several other re-
ports demonstrated that monocytes express high levels of
Siglec-7 [9,11,12,46,52]. In our experiments, the constitutive
expression of Siglec-7 on monocytes paralleled the ones ob-
served on NK cells [13], and remained very high on MDMs
even after 7 days of culture with GM-CSF although at lower
levels if compared to freshly isolated monocytes.
Given the ability of Siglec-7 fusion protein to enhance
in vitro HIV-1 infection of CD4pos T cells, we then deter-
mined whether different levels of sSiglec-7 released during
the course of HIV-1 infection are associated with different
clinical outcomes. We did not find any significant differ-
ences in the serum levels of sSiglec-7 between healthy con-
trols and several different cohorts of HIV-1 infected
patients. However, AIDS patients showed a trend toward
increase of Siglec-7 in their sera compared to healthy do-
nors and, in particular, we found a direct and statistically
significant correlation between HIV-RNA and serum levels
of Siglec-7 in naïve HIV-1 infected patients, suggesting that
a higher viral burden could induce the shedding of Siglec-7
in serum. In this regard, it is conceivable to hypothesize
that a possible source of sSiglec-7 are NK cells, since we
demonstrated that the exposure of these cells to high
chronic HIV-1 viremia induce the expansion of pathological
NK cell subsets showing an aberrant receptor repertoire
and an unusual negative expression of Siglec-7 [53,54]. The
fact that Siglec-7 fusion protein enhances the in vitro sus-
ceptibility of CD4pos T cells to be infected by HIV-1 is also
consistent with the persistent high levels of HIV-1viremia, with the high amount of sSiglec-7 and with low
CD4pos T cell counts found in AIDS patients. Interestingly, a
CD56neg/Siglec-7neg population associated with high levels
of HIV-1 viremia has been described as a dysfunctional NK
cell subset that is significantly expanded in the late stages of
HIV-1 infection [31]. In agreement with this, sSiglec-7 was
found to be significantly increased in the sera of patients
with viral load over 10,000 copies/ml, suggesting a possible
role for this lectin-type receptor as a biological marker in-
volved in the disease progression. We are currently testing
this hypothesis in a larger patient cohort. Finally, an inverse
correlation between the serum levels of Siglec-7 and
CD4pos T cell counts was observed in AIDS patients, which
were also the cohort of HIV-1 infected subjects with the
highest serum levels of sSiglec-7. These findings lead us to
hypothesize that the presence of remarkable amounts of
sSiglec-7, together with a low CD4pos T cell count, high
levels of HIV-1 viremia and expansion of Siglec-7neg NK
cells, characterize the advanced stages of HIV infection.
For our experimental approaches testing the ability
sSiglec-7 to enhance the infection of CD4pos PM1 cell line
and primary T cells, we used a dose of fusion protein
(10 μg/ml) much higher compared to amount of sSiglec-7
found in the sera of both healthy donors and HIV-1 in-
fected patients (floating within a ng/ml range). We have
chosen to use a higher sSiglec-7 concentration in our
in vitro approach to maximize ligand-receptor binding.
However, it must be emphasized that identical concentra-
tions of an irrelevant protein such as soluble NKp44 was
unable to promote infection using the same experimental
conditions. Moreover, even though the serum concentra-
tions of sSiglec-7 in HIV-1 infected patients or healthy do-
nors are remarkably lower compared to those used in our
in vitro approach, it remains to be determined the amounts
of this soluble protein during acute phases of infection
when HIV-1 viral load is in the ranges of several hundred-
thousand copies [31]. Finally, we need to assess whether
higher levels of sSiglec-7 are also observed at gut or cervix
mucosal levels, two of the main gates of viral entrance
[55,56]. Indeed, macrophages as well as NK and T cells play
an active role within these tissue sites in context of innate
and adaptive immune responses and establishment of viral
reservoirs in the CD4pos targets [57-59].
Conclusions
Our study shows that HIV-1 infection of target cells is
modulated by Siglec-7, which both enhances viral entry in
Siglec-7neg/CD4pos T cells in its soluble form and partici-
pates to the infection of Siglec-7pos MDMs (Figure 7).
These results, together with the positive correlations be-
tween sSiglec-7 and viral load in the sera of HIV-1 infected
naïve patients and with our previous data showing a patho-
logic expansion of highly dysfunctional CD56neg/Siglec-7neg
cells in AIDS patients [31], prompt us to hypothesize that
BA
Figure 7 Siglec-7 and susceptibility to HIV-1 infection. A, Chronic and high levels of HIV-1 replication in AIDS patients lead to the decreased surface
expression of Siglec-7 on NK cells [31] and to higher levels of soluble Siglec-7 detected in the plasma of HIV-1 infected patients with elevated viral burden
(Figures 5 and 6). HIV-1 is able to bind Siglec-7 (Figure 1) that, in its soluble form facilitates the infection of Siglec-7neg/CD4pos T cells (Figures 3 and 4). B, In
contrast, high levels of viral replication do not affect the constitutive expression on monocytes and macrophage of Siglec-7 [14-31], which in turns,
significantly contribute to HIV-1 infection of these cells. These experimental evidence suggest that, similar to other members of Siglec family [28-30],
Siglec-7 greatly enhances either in its soluble form or as membrane receptor the susceptibility of CD4pos cell targets expressing chemokine receptors
to be infected by HIV-1, while spares from infection NK cells that, although positive for CCR5 or CXCR4, do not express CD4 [54].
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pathogenesis by being associated with an higher susceptibil-
ity of CD4pos target cells to be infected and with disease
progression. The disclosure of these novel insights might
lead to the use of Siglec-7 as potential biomarker during
the course of HIV-1 infection and to therapeutically target
this lectin-type receptor in order to inhibit viral replication/
spreading thus limiting the depletion of CD4pos T cells and
the establishment of viral reservoirs.
Methods
Patients
Peripheral blood mononuclear cells (PBMCs) were ob-
tained from buffy coat in accordance with the clinical
protocol approved by the Institutional Review Board (IRB)
of San Matteo Hospital, Pavia, Italy. The sera of HIV-1 in-
fected patients (Table 1) were obtained in accordance withthe clinical protocol approved by the IRB of Sacco Hospital,
Milan, Italy. Donors from both protocols signed consent
forms that were approved by the above-mentioned IRBs in
accordance with Italian laws and with Declaration of
Helsinki.
Reagents
Recombinant human Siglec-7 and NKp44 fusion proteins
and blocking anti-Siglec-7 polyclonal Ab were purchased
from R&D system Inc. Commercially available ELISA kits
were used for the detection of HIV-1 gp120 (Perkin Elmer)
and sSiglec-7 (DuoSet, R&D system). Recombinant gp120s
and anti-gp120 HIV-1 monoclonal Ab (mAb) 2G12 were
obtained from the National Institutes of Health AIDS Re-
search and Reference Reagent Program. Anti-Siglec-7
monoclonal Abs (mAbs) QA79 and Z176 were purchased
from Instrumentation Laboratories.
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Gp120 from HIV-1 IIIB strain was covalently conju-
gated to carboxyl microparticles using the PolyLink
Protein coupling kit (Bangs Laboratories Inc.) following
the manufacturer instructions. Siglec-7-Fc or NKp44-Fc
fusion proteins were incubated with BioMag particles
coated with goat anti-human IgG Fc Abs (Qiagen) in
order to bind the beads.
Siglec-7 binding to gp120
260 ng of gp120-conjugated beads (130 μg/ml) were incu-
bated with 1 μg of Siglec-7-Fc or NKp44-Fc protein for 30’
at RT. After three washing, a phycoerythrin (PE) polyclonal
goat anti-human-Fc was added for 30’ at 4°C. Samples were
then washed and analyzed with a Facscalibur flow cyt-
ometer (BD Biosciences). Data were analyzed using FlowJo
software (TreeStar).
Sialidase treatment was performed incubating 0.16 units/
ml of Vibrio cholerae neuraminidase (Sigma) in DMEM
medium with gp120 coated beads for 2 hours at 37°C.
Flicking of the tubes was done every 20’ to get a uniform
treatment of sialidase. Beads were washed three times with
DMEM 10% FCS.
Virus binding assay
10 μg of Siglec-7-Fc or NKp44-Fc proteins conjugated to
magnetic beads were incubated with viral stocks of different
HIV-1 strains (IIIB, SG, BaL; 5 × 105 copies/ml). After three
washing steps with complete, culture medium samples were
solubilized in lysis buffer (250 μl of 0.5% NP40 alternative,
Calbiochem-Merck), bead debris were removed by mag-
netic adhesion and the concentration of p24 protein re-
leased in the buffer was measured by ELISA. The binding
of R5 or X4 HIV-1 isolates to beads coated with the anti-
gp120 mAb 2G12 was used a positive internal control.
Cells
PM1 cells were cultured in RPMI 1640 medium (Sigma)
supplemented with 10% fetal calf serum (HyClone
South Logan), 2 mM L-glutamine (Sigma) and antibiotics
(100 U/ml penicillin, 0.1 μg/ml streptomycin, 0.25 μg/ml
amphotericin B, Sigma). CD4+ T cells and CD14+ mono-
cytes were isolated from PBMCs by negative magnetic se-
lection (EasySep, Stemcell) from PBMCs obtained by
healthy donors by standard density gradient centrifugation
(Lympho Separation Medium, MP Biomedicals). The pur-
ity of both populations was always higher than 95%.
Monocytes were cultured at 5 × 105 cells/ml in 48-well
plates in RPMI 1640 supplemented with 10% fetal bovine
serum (HyClone South Logan), 10% human serum AB
(EuroClone S.p.A.), 2 mM L-glutamine (Sigma), antibiotics
(100 U/ml penicillin, 0.1 mg/ml streptomycin, 0.25 mg/ml
amphotericin B, Sigma) and 10 ng/ml GM-CSF for 7 days
with medium replacement every 3 days. We analyzed thesurface expression of Siglec-7, CD14 and CD33 (BD Phar-
migen) on MDMs after 8 days of culture, in the presence of
20% human serum to avoid non-specific binding to Fc-
receptors.
Flow cytometry
For multicolour (up to 8 colours) (FACS Fortessa, BD
Pharmigen) flow cytometric analyses, PBMCs were stained
with Brilliant Violet 421-labeled CD56, fluorescein isothio-
cyanate (FITC)-labeled CD3, Pacific Blue-labeled CD14
(Biolegend), allophycocyanin(APC)-labeled CD4 (R&D sys-
tem), PerCP-labeled CD8, APC/C7-labeled 19, PC7-labeled
CD16, phycoerythrin(PE)-labeled CD32 and CD64 (BD
Pharmigen) monoclonal antibodies (mAbs). Viable cells
were detected through the aqua live/dead staining,
according to manufacturer instructions (Invitrogen).
Within the lymphocyte gate, CD4pos T cells were de-
fined as CD3pos, CD19neg, CD56neg, CD8neg cells, while
monocytes were defined as CD14pos cells within the re-
lated gate. PM1 T cell cell lines were gated within the
CD4pos cells [60,61]. Data were analyzed by using FlowJo
software (TreeStar).
Blocking of HIV-1 binding to MDMs by anti-Siglec-7
masking antibody
MDMs were treated with 10 μg/ml of anti-Siglec-7 block-
ing polyclonal Ab or IgG isotype control (R&D System) in
the presence of 20% human serum for 1 hour at 4°C. After
three washing with PBS 2% FCS cells were infected as de-
scribed below.
HIV-1 infection of CD4+ cells
CD4+ PM1 T cells or primary CD4+ T cells were infected
with either HIV-1BaL or HIV-1IIIB viruses. HIV-1 strains
were propagated in phytohemagglutinin (PHA)-activated
PBMC and collected from cell supernatant at peak times
of HIV-RNA content. Cells (1 × 106/ml, 2 × 105/well) were
inoculated with HIV-1 stock (5 × 105 HIV-RNA copies/
well) previously treated (for 1 hour at 37°C) with Siglec-7-
or NKp44-Fc protein (10 μg/ml) and cultured at 37°C in
20% FCS RPMI 1640 medium. HIV-RNA was evaluated in
cell supernatants after 3 days of culture.HIV-1 entry assay
After 4 hour incubation with HIV-virus (5 × 105 copies/
well) CD4+ T cells (1 × 106/ml, 2 × 105/well) or MDMs
(5 × 105 cells/ml, 5 × 105 cells/well) were washed twice and
treated with trypsin (2.5 mg/ml) for 10’ at 37°C to remove
the extracellular virus adherent to the cell surface. After
three additional washing steps with complete culture
medium, cell lysates were prepared with NP40 Alternative
0.5% (Calbiochem-Merck) and the concentration of HIV-
RNA was measured by real-time PCR.
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The evaluation of HIV replication capacity was deter-
mined by measuring the HIV-RNA copy numbers in cell
culture supernatants or, for entry assay, in the cell lysate
after elimination of cell debris. In detail, viral HIV-1 RNA
was extracted from supernatants or cell extracts using the
automatic Easy Mag extractor (Biomerieux, Lyon, France)
and quantified by real time PCR targeting a conserved re-
gion in the long terminal repeat (LTR) as previously re-
ported [62].
Statistical analysis
Paired t test was used to compare the HIV IIIB-beads
binding to Siglec-7 Fc-chimera protein. One-way ANOVA
statistical test followed by a Bonferroni post-test was used
to compare HIV-RNA copies/ml within the different
experimental settings, while Kruskal Wallis statistical test
followed by a Dunn post-test to compare the serum levels
of sSiglec-7 in the different groups of HIV infected pa-
tients. Pearson correlation test was used to correlate
sSiglec-7 with HIV-RNA levels or CD4+ cell numbers.Additional files
Additional file 1: Figure S1. Surface expression of CD64 (FCγRI) on
PM1 cell line and CD4pos primary T cells. Flow cytometric dot plot graphs
showing the surface expression of CD64 (lower line) compared to the
related isotypes (upper line) from a representative healthy donor out of
three independent experiments performed. CD14pos monocytes were
chosen as positive control.
Additional file 2: Figure S2. Surface expression of CD32 (FCγRII) on
PM1 cell line and CD4pos primary T cells. Flow cytometric dot plot graphs
showing the surface expression of CD32 (lower line) compared to the
related isotypes (upper line) from a representative healthy donor out of
three independent experiments performed. CD14pos monocytes were
chosen as positive control.
Additional file 3: Figure S3. Surface expression of CD1 6(FCγRIII) on
PM1 cell line and CD4pos primary T cells. Flow cytometric dot plot graphs
showing the surface expression of CD16 (lower line) compared to the
related isotypes (upper line) from a representative healthy donor out of
three independent experiments performed. CD56pos NK cells were
chosen as positive control.Abbreviations
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